Integer to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During MD&M West 2026
MWN-AI** Summary
Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), is set to showcase its advanced integrated R&D solutions and expanded coating capabilities at MD&M West 2026 in Anaheim, California, from February 3 to 5. The company will debut a substantial 20 x 50 sq. ft. exhibition booth (#3201), presenting its comprehensive range of customer solutions designed to streamline medical device development.
At the forefront of Integer’s exhibit will be R&D Velocity, a robust integrated ecosystem that connects design, prototyping, and manufacturing processes. This unique ecosystem enables medical device companies to produce manufacturable designs from the outset, thus accelerating the journey from concept to market. Andrew Senn, President of Cardio & Vascular, explained that Integer is dedicated to helping clients design effectively for production across various medical fields, including cardiac rhythm management and neurovascular solutions.
Integer's R&D Velocity facilitates a seamless transition through several key offerings: Differentiated Technology Platforms, global capabilities and expertise with specialized labs, designs optimized for manufacturability, and rapid prototyping that can deliver working prototypes in as little as two weeks. Additionally, Integer will display an extensive coatings portfolio, which includes PTFE and hydrophilic coatings, as it enhances its role as a fully integrated coating partner for medical devices.
Highlighting its commitment to innovation, Integer will exhibit miniaturized technologies for cardiac rhythm management, complex catheters, and therapy delivery systems. Jim Stephens, President of Cardiac Rhythm Management and Neuromodulation, emphasized the end-to-end approach that equips customers to efficiently bring high-quality medical devices to market.
Attendees are encouraged to visit Integer’s booth #3201 to explore the company’s latest advancements. For more information, visit www.integer.net.
MWN-AI** Analysis
Integer Holdings Corporation (NYSE: ITGR) is poised to enhance its market position dramatically through its participation at MD&M West 2026 by showcasing its integrated R&D solutions and expanded coating capabilities. Investors should consider this as a pivotal moment that could potentially drive stock value upwards, given the company’s strategic innovations and market insights presented at the event.
Integer’s R&D Velocity initiative is a game changer, connecting design, prototyping, and manufacturing within a seamless ecosystem. This approach not only accelerates product development cycles but also optimizes designs for manufacturability from the outset, aligning with the increasing demand for efficiency in medical device production. The emphasis on reducing iterations allows Integer to cater to a diverse clientele ranging from structural heart delivery systems to neuromodulation devices, reflecting a broad market applicability.
Additionally, Integer’s expanded capabilities in coatings signify a pronounced commitment to becoming a fully integrated partner for medical device manufacturers. With recent acquisitions, the company now offers advanced surface-modification solutions that enhance the functionality of medical devices. This is critical for meeting the precision and quality standards of today’s healthcare technologies.
The company’s demonstrated expertise in cardiac rhythm management and vascular solutions should not be overlooked either. As medical advancements progress, Integer’s commitment to miniaturization and complex technology showcases its readiness to meet future demand in these growing sectors.
For investors, Integer presents a substantial growth opportunity driven by its strategic expansions in R&D and coating technologies. Potential buyers may want to capitalize on the anticipated positive market response following the event by considering stock purchases after MD&M West 2026. Overall, Integer's position as a leader in the medical device space and its focus on innovation positions it favorably for future returns.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PLANO, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will exhibit during MD&M West 2026 in Anaheim, Calif., Feb. 3 – 5.
Integer will unveil a significantly expanded 20 x 50 sq. ft. new booth #3201, showcasing the company’s full range of customer solutions.
On prominent display will be R&D Velocity, Integer’s integrated R&D ecosystem connecting design, prototyping and manufacturing to help medical device companies develop products that are manufacturable from the start, accelerating the time between design and manufacturability.
“Whether you’re advancing structural heart delivery systems, neurovascular catheters, electrophysiology tools, peripheral vascular therapies, or cardiac rhythm management and neuromodulation devices, Integer helps customers design products right the first time — with production in mind,” said Andrew Senn, President, Cardio & Vascular. “Through expert engineers, advanced labs, rapid prototyping, development and scalable manufacturing under one ecosystem, Integer R&D Velocity helps medical device companies bridge the gap between early concepts and real-world production, reducing iterations and expediting development cycles.”
The company will showcase several solutions – delivered through a network of locations globally – that are central to R&D Velocity, including:
- Differentiated Technology Platforms: Proven product technologies that enable, accelerate and de-risk the development of our customers’ next generation devices
- Global Capabilities and Expertise: Specialized labs and integrated manufacturing all in one ecosystem along with dedicated engineers and global centers of excellence to accelerate every phase of development.
- Ease of Manufacturability: Designs optimized early to scale seamlessly, reducing rework and accelerating launch.
- Rapid Prototyping: Engineer-to-engineer collaboration delivering prototypes in as little as two weeks.
Integer will additionally highlight a range of key product areas and innovations during MD&M West, including:
- Integer Medical Coatings: The company continues to expand its role as a fully integrated coating partner for medical devices, strengthening its ability to deliver end-to-end surface-modification solutions. Integer will also showcase its full coatings portfolio, including PTFE, PTFE alternatives, hydrophilic coatings, parylene, and advanced surface-modification technologies. Following the acquisitions of Precision Coating, VSi Parylene, and certain Biocoat assets last year, Integer has further strengthened its position as a fully integrated coating partner for medical devices.
- Cardiac Rhythm Management and Neuromodulation: Miniaturized technologies for finished IPG systems, as well as Gen 3 Li-Ion and Gen 2 CFx batteries.
- Cardio and Vascular: A full range of electrophysiology, structural heart, and neurovascular product solutions including complex catheters, guidewires, steerable introducers and sheaths, therapy delivery systems and implant technologies.
“With an end-to-end ecosystem that connects design, development and global manufacturing, Integer empowers customers to streamline development and bring high-quality medical devices to market more efficiently,” said Jim Stephens, President, Cardiac Rhythm Management and Neuromodulation. “We’re excited to share our latest capabilities during MD&M West and encourage attendees to meet the team and see what’s possible at booth #3201.”
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company’s brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Kristen Stewart | Misty Tippen |
| kristen.stewart@integer.net | misty.tippen@integer.net |
| 551.337.3973 | 469.536.6702 |
FAQ**
How will Integer Holdings Corporation (ITGR) leverage its R&D Velocity ecosystem to enhance product development efficiency for medical device companies at the MD&M West 2026?
What new innovations and technologies will Integer Holdings Corporation (ITGR) showcase in the cardiac rhythm management and neuromodulation sectors during the MD&M West exhibit?
How does Integer Holdings Corporation (ITGR) plan to address the ease of manufacturability in design optimization to reduce rework and accelerate product launches?
In what ways do Integer Holdings Corporation's (ITGR) recent acquisitions, such as Precision Coating and VSi Parylene, strengthen its position as a fully integrated coating partner for medical device manufacturers?
**MWN-AI FAQ is based on asking OpenAI questions about Integer Holdings Corporation (NYSE: ITGR).
NASDAQ: ITGR
ITGR Trading
3.05% G/L:
$87.085 Last:
341,269 Volume:
$83.48 Open:
